ClinicalTrials.gg
Not yet recruitingNCT07201181Updated Jul 21, 2026

Prenatal Tobacco Exposure and Newborn Outcomes: A Maternal Urinary Cotinine Study

An observational study in Tobacco Smoke Pollution, Maternal Exposure During Pregnancy and Infant, Newborn, sponsored by Haseki Training and Research Hospital. Not yet recruiting. Open to participants aged 0 Minutes to 72 Hours, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Haseki Training and Research Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
126
Ages
0 Minutes to 72 Hours
Sex
All
01

Study summary

Prenatal exposure to tobacco smoke, through either active maternal smoking or secondhand exposure, has been associated with impaired fetal oxygenation, metabolic stress, and adverse early neonatal outcomes. This prospective, single-center observational cohort study will objectively assess maternal tobacco exposure using cotinine measured in maternal urine and examine its association with early neonatal biochemical, metabolic, and clinical outcomes.

Consecutive eligible mother-newborn dyads will be recruited at a tertiary academic hospital after written informed consent is obtained. A clean-catch midstream maternal urine sample will be collected within 24 hours before delivery, preferably at admission to the delivery unit and before intravenous fluid administration, for quantitative cotinine and creatinine measurement. Maternal tobacco exposure will be assessed using the urinary cotinine concentration, the cotinine-to-creatinine ratio, and maternal self-reported smoking and secondhand smoke exposure. Based on prespecified biomarker thresholds and exposure history, participants will be classified as having active exposure, passive exposure, or no exposure. No experimental intervention will be administered.

Neonatal data will include umbilical cord blood gas parameters, including pH, pCO2, pO2, base excess, bicarbonate, lactate, and fetal carboxyhemoglobin (FCOHb). Birthweight, length, head circumference, Apgar scores, oxygen saturation, heart rate, and blood pressure will also be recorded. Routine laboratory measurements obtained during the early postnatal period will include complete blood count parameters, hematologic and inflammatory indices such as NLR and PLR, albumin, the albumin-to-lactate ratio, HDL, LDL, and other routinely available biochemical markers. Thyroid-stimulating hormone results from the national newborn screening program and newborn hearing screening results will be recorded. Postnatal weight loss and bilirubin measurements from routine follow-up visits will also be collected when available.

The primary objective is to determine whether increasing maternal urinary cotinine exposure is associated with higher umbilical cord blood lactate and FCOHb levels, indicating greater metabolic stress and impaired fetal oxygenation. Secondary objectives include evaluating associations with cord blood gas parameters, birthweight, early hematologic and biochemical indices, albumin and the albumin-to-lactate ratio, blood pressure, bilirubin levels, thyroid screening results, and hearing screening outcomes.

Maternal, obstetric, and perinatal variables, including maternal age, parity, gestational age, mode of delivery, smoking history, intrapartum factors, and relevant maternal comorbidities, will be recorded for adjusted analyses. Statistical analyses will include comparisons among the three exposure groups and multivariable regression models evaluating urinary cotinine both as a continuous measure and as a categorical exposure variable.

This study is designed to provide prospectively collected, biomarker-verified evidence regarding the relationship between maternal tobacco exposure and immediate neonatal metabolic, hematologic, and physiologic outcomes using measurements that are feasible within routine clinical care.

02

Conditions studied

  • Tobacco Smoke Pollution
  • Maternal Exposure During Pregnancy
  • Infant, Newborn
  • Carbon Monoxide Poisoning

Keywords

  • Prenatal Tobacco Exposure
  • Maternal Smoking
03

In context

Carbon Monoxide Poisoning

44 studies on the registry are indexed under Carbon Monoxide Poisoning; 8 are open to participants now.

This study's planned enrollment of 126 is above the median of 104 across 25 observational studies indexed under Carbon Monoxide Poisoning.

Browse Carbon Monoxide Poisoning studies →

Lead sponsor

Haseki Training and Research Hospital is the lead sponsor of 78 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Minutes to 72 Hours
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This is a single-center prospective cohort study conducted at a tertiary hospital. Consecutive eligible mother-newborn dyads are recruited during the delivery hospitalization. Maternal clean-catch urine is collected within 24 hours before delivery for cotinine and creatinine measurement. Dyads are classified as active exposure, passive exposure, or no exposure according to prespecified urinary cotinine-to-creatinine thresholds and maternal exposure history.

Outcomes are obtained mainly from routine care and include cord blood lactate, pH, base excess, FCOHb, birthweight, anthropometric measurements, Apgar scores, vital signs, early laboratory results, newborn screening TSH, hearing screening, and follow-up weight loss and bilirubin where available. No experimental intervention or additional neonatal blood sampling is planned.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant individual expected to deliver a liveborn infant at the study hospital and providing written before delivery.
  • Singleton pregnancy with an anticipated gestational age of ≥35 completed weeks at delivery.
  • Maternal clean-catch urine sample obtainable within 24 hours before delivery, preferably at admission and before intravenous fluid administration, for urinary cotinine and creatinine measurement.
  • Availability of routine umbilical cord blood gas analysis at birth, including at minimum lactate, pH, and base excess, with fetal carboxyhemoglobin recorded when available.
  • Availability of routine neonatal clinical data, including birthweight, anthropometric measurements, Apgar scores, vital signs, and early postnatal assessments according to unit practice.

Exclusion criteria

Exclusion Criteria:

  • Multiple gestation.
  • Major congenital anomaly, known chromosomal or genetic disorder, or major metabolic disease likely to affect neonatal adaptation or the study outcomes.
  • Emergency clinical circumstances in which obtaining or the maternal urine sample could delay or interfere with urgent maternal or neonatal care.
  • Inability to obtain an adequate maternal urine sample before delivery for cotinine and creatinine measurement.
  • Severe perinatal condition preventing acquisition or reliable interpretation of the primary outcome data, including major birth trauma or prolonged intensive care requirement.
  • Missing umbilical cord blood lactate measurement or other critical primary outcome data.
  • Previous enrollment of the same mother-newborn dyad.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
126 participants (estimated)
Patient registry
No

Groups and cohorts

  • Active Prenatal Tobacco Exposure (Maternal Urinary Cotinine-Defined)

    Mother-newborn dyads in whom the maternal urinary cotinine-to-creatinine ratio is consistent with active tobacco exposure according to the prespecified study threshold. Maternal self-reported smoking and secondhand smoke exposure will also be recorded as supportive exposure information. Neonatal outcomes will include umbilical cord blood gas parameters, including pH, pCO2, pO2, base excess, bicarbonate, lactate, and fetal carboxyhemoglobin (FCOHb); birthweight and other anthropometric measurements; Apgar scores; oxygen saturation; heart rate; blood pressure; and routine laboratory measurements obtained during the early postnatal period. Laboratory variables will include complete blood count parameters, NLR, PLR, albumin, the albumin-to-lactate ratio, HDL, LDL, and other routinely available biochemical markers. Newborn screening TSH, hearing screening results, postnatal weight loss, and bilirubin measurements will also be recorded where available.

    Other: Maternal Urinary Cotinine Assessment

  • Passive Prenatal Tobacco Exposure (Maternal Urinary Cotinine-Defined)

    Mother-newborn dyads in whom the maternal urinary cotinine-to-creatinine ratio is detectable but below the active-exposure threshold and is consistent with passive prenatal tobacco exposure according to the prespecified study thresholds. Maternal self-reported smoking and secondhand smoke exposure will also be recorded as supportive exposure information. The same neonatal biochemical, metabolic, physiologic, and clinical measurements will be collected as in the active-exposure and reference cohorts. No experimental intervention will be administered.

    Other: Maternal Urinary Cotinine Assessment

  • No Prenatal Tobacco Exposure (Maternal Urinary Cotinine-Defined Reference Cohort)

    Mother-newborn dyads in whom the maternal urinary cotinine-to-creatinine ratio is below the prespecified no-exposure threshold or below the analytical detection limit. Maternal smoking and secondhand smoke exposure history will also be recorded to assess agreement between biomarker-based and self-reported exposure classifications. The same neonatal biochemical, metabolic, physiologic, and clinical measurements will be collected as in the exposed cohorts. No experimental intervention will be administered.

    Other: Maternal Urinary Cotinine Assessment

Interventions

  • OtherMaternal Urinary Cotinine Assessment

    A clean-catch midstream maternal urine sample will be collected within 24 hours before delivery, preferably at admission to the delivery unit and before intravenous fluid administration. Urinary cotinine and creatinine concentrations will be measured, and the cotinine-to-creatinine ratio will be used to objectively classify prenatal tobacco exposure. No treatment or behavioral intervention will be assigned.

06

What researchers measure

Primary outcomes

  1. Umbilical Cord Blood Lactate

    Umbilical cord blood lactate concentration measured using routine blood gas analysis. Lactate levels will be compared across maternal urinary cotinine-defined exposure groups (active, passive, and no exposure) and evaluated in multivariable regression models with adjustment for relevant maternal and perinatal factors. Unit of Measure: mmol/L.

    Time frame: At birth (sample obtained within 10 minutes of delivery; analyzed within routine lab turnaround)

Secondary outcomes

  1. Umbilical Cord Blood pH

    Arterial/venous cord blood pH per routine gas analysis; association with maternal cotinine exposure categories. Unit of Measure: pH units

    Time frame: At birth (within 10 minutes)

  2. Umbilical Cord Blood Base Excess (BE)

    Base excess from routine cord gas; group comparisons and adjusted models parallel to primary analysis. Unit of Measure: mEq/L

    Time frame: At birth (within 10 minutes)

  3. Fetal Carboxyhemoglobin (FCOHb)

    Percent carboxyhemoglobin from cord blood CO-oximetry; tested for dose-response with maternal urinary cotinine. Unit of Measure: percent

    Time frame: At birth (same cord sample, routine CO-oximetry if available)

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Abraham M, Alramadhan S, Iniguez C, Duijts L, Jaddoe VW, Den Dekker HT, Crozier S, Godfrey KM, Hindmarsh P, Vik T, Jacobsen GW, Hanke W, Sobala W, Devereux G, Turner S. A systematic review of maternal smoking during pregnancy and fetal measurements with meta-analysis. PLoS One. 2017 Feb 23;12(2):e0170946. doi: 10.1371/journal.pone.0170946. eCollection 2017. PubMed 28231292 ↗
  • Filis P, Hombach-Klonisch S, Ayotte P, Nagrath N, Soffientini U, Klonisch T, O'Shaughnessy P, Fowler PA. Maternal smoking and high BMI disrupt thyroid gland development. BMC Med. 2018 Oct 23;16(1):194. doi: 10.1186/s12916-018-1183-7. PubMed 30348172 ↗
  • Di HK, Gan Y, Lu K, Wang C, Zhu Y, Meng X, Xia WQ, Xu MZ, Feng J, Tian QF, He Y, Nie ZQ, Liu JA, Song FJ, Lu ZX. Maternal smoking status during pregnancy and low birth weight in offspring: systematic review and meta-analysis of 55 cohort studies published from 1986 to 2020. World J Pediatr. 2022 Mar;18(3):176-185. doi: 10.1007/s12519-021-00501-5. Epub 2022 Jan 28. PubMed 35089538 ↗
  • Berlin I, Heilbronner C, Georgieu S, Meier C, Spreux-Varoquaux O. Newborns' cord blood plasma cotinine concentrations are similar to that of their delivering smoking mothers. Drug Alcohol Depend. 2010 Mar 1;107(2-3):250-2. doi: 10.1016/j.drugalcdep.2009.10.008. Epub 2009 Nov 24. PubMed 19939584 ↗
  • Hayde M, Bernaschek G, Stevenson DK, Knight GJ, Haddow JE, Widness JA. Antepartum fetal and maternal carboxyhemoglobin and cotinine levels among cigarette smokers. Acta Paediatr. 1999 Mar;88(3):327-31. doi: 10.1080/08035259950170123. PubMed 10229047 ↗
  • Wang X, Tager IB, Van Vunakis H, Speizer FE, Hanrahan JP. Maternal smoking during pregnancy, urine cotinine concentrations, and birth outcomes. A prospective cohort study. Int J Epidemiol. 1997 Oct;26(5):978-88. doi: 10.1093/ije/26.5.978. PubMed 9363518 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Nov 2026, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2025
First posted
Oct 1, 2025
StartEst.
Aug 1, 2026
Primary completionEst.
Nov 8, 2026
CompletionEst.
Jan 1, 2027
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07201181
Lead sponsor
Haseki Training and Research Hospital
Responsible party
Berker Okay (MD - Pediatrician (Principal Investigator), Haseki Training and Research Hospital) — Principal investigator
First posted
Oct 1, 2025
Start date
Aug 1, 2026 (estimated)
Primary completion
Nov 8, 2026 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Jul 21, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion